



PharmaZen Limited reports record performance to 31 December 2019

The PharmaZen Board of Directors announced today an unaudited full year pre-tax profit of \$4,014,000 on sales of \$17.3 million.

This record result is an increase in sales of 38% and an increase in pre-tax profit of 124% over the 2018 year result.

EBITDA for the period was \$5.4 million which is nearly double the \$2.74 m achieved in 2018.

	2019	2018	Incr over prior year	
	000's	000's	000's	%
Total Revenue	17,317	12,573	4,744	38%
EBITDA	5,431	2,740	2,691	98%
Profit before tax	4,014	1,792	2,223	124%

Chair of the Board Ken Fergus said “Demand has continued to grow across the company’s range of products and we would expect demand to increase even further as people become more concerned about health issues with the Covid-19 pandemic. The 2019 financial performance has validated our decision to increase our spend on capital equipment and I am extremely pleased by the speed staff have been able to have new plant and equipment operating at such high levels of output and efficiency”.

Ken Fergus
Chairman
 March 23, 2020